GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Dec 12, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-repurchase, company-news
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
GSK plc announced on December 12, 2025, that it has purchased a certain number of its own ordinary shares through its broker, BNP Paribas SA. This transaction is part of the company's ongoing share repurchase program.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — The company making the announcement and repurchasing shares.
- BNP Paribas SA (company) — The broker acting on behalf of GSK plc for the share purchases.
FAQ
What specific number of GSK plc ordinary shares were purchased?
The filing states that a 'certain number' of shares were purchased, but the exact quantity is not specified in the provided text.
On what date did GSK plc announce this transaction?
GSK plc announced the transaction on December 12, 2025.
Who is acting as the broker for these share repurchases?
BNP Paribas SA is acting as the broker for GSK plc's share repurchases.
Is GSK plc filing this report under Form 20-F or Form 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
What is the principal executive office address of GSK plc?
The principal executive office address of GSK plc is 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 3,067 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-12-12 08:43:07
Filing Documents
- a2856l.htm (6-K) — 3184KB
- 0001654954-25-013879.txt ( ) — 3185KB
From the Filing
IN OWN SHARES a2856l   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of December 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .             Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 11 December 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 217,000 Lowest price paid per share (GBp): 1,793.00p Highest price paid per share (GBp): 1,820.00p Volume-weighted average price paid per share (GBp): 1,807.53p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 13,161,733 ordinary shares.   Following the above purchase, the Company will hold 238,626,577 ordinary shares in treasury and have 4,076,812,560 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,076,812,560. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.85 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:     GSK plc (ISIN: GB00BN7SWP63) Date of purchases:      11 December 2025 Investment firm:         BNP Paribas SA     Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   17,501   1,820.00p   1,794.00p   1,808.30p   CHIX   65,566   1,820.00p   1,793.00p   1,807.54p   XLON   133,933   1,820.00p   1,793.50p   1,807.43p       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   63   1803.5   XLON   11-Dec-2025   08:00:39   20251211158681519   126   1803.5   XLON   11-Dec-2025   08:01:03   20251211158681837   245   1802.5   CHIX   11-Dec-2025   08:01:06   20251211158681923   108   1802.0   CHIX   11-Dec-2025   08